Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Head and Neck Cancer Resource Center

Featured

News
Analyzing Billing Patterns and Medicare Reimbursement Among Otolaryngologists Performing In-Office Cerumen Removal
09/12/2022

Yvette C Terrie

Yvette C Terrie
General physicians and other providers are progressively referring patients requiring cerumen disimpaction to otolaryngologist physicians and permitting advanced practice providers to perform these procedures, suggesting a shift in landscape...
General physicians and other providers are progressively referring patients requiring cerumen disimpaction to otolaryngologist physicians and permitting advanced practice providers to perform these procedures, suggesting a shift in landscape...
General physicians and other...
09/12/2022
Journal of Clinical Pathways
News
Model Predicts Presence of Occult Nodal Metastasis Better Than Current Standard in Early-Stage Oral Cavity Squamous Cell Carcinoma
05/18/2022

Ellen Kurek

Ellen Kurek
Machine learning models that were developed from multi-institutional clinicopathologic data may reduce the number of pathologically node-negative neck dissections and accurately identify patients with early OCSCC who are at highest risk for...
Machine learning models that were developed from multi-institutional clinicopathologic data may reduce the number of pathologically node-negative neck dissections and accurately identify patients with early OCSCC who are at highest risk for...
Machine learning models that...
05/18/2022
Journal of Clinical Pathways
News
Decision Analytical Model Optimizes Posttreatment Surveillance Strategies Among Patients With Oropharyngeal Carcinoma
04/29/2022

Marta Rybczynski

Marta Rybczynski
When compared with common medical reimbursement guidelines, model-optimized strategies may be associated with lower detection latency without requiring any additional imaging studies among patients with oropharyngeal carcinoma.
When compared with common medical reimbursement guidelines, model-optimized strategies may be associated with lower detection latency without requiring any additional imaging studies among patients with oropharyngeal carcinoma.
When compared with common...
04/29/2022
Journal of Clinical Pathways
News
Medicare Reimbursement Decreased from 2000 to 2020 in Head and Neck Surgical Oncology
04/26/2022

Ellen Kurek

Ellen Kurek
Medicare reimbursement decreased from 2000 through 2020 for the 37 most common head and neck surgical oncologic procedure codes considered as a group, according to a recent analysis.
Medicare reimbursement decreased from 2000 through 2020 for the 37 most common head and neck surgical oncologic procedure codes considered as a group, according to a recent analysis.
Medicare reimbursement decreased...
04/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Imaging Use Among Patients With Head and Neck Cancer
01/28/2022
True or False: Many patients with head and neck cancers receive imaging beyond what is recommended by the NCCN guidelines.
True or False: Many patients with head and neck cancers receive imaging beyond what is recommended by the NCCN guidelines.
True or False: Many patients...
01/28/2022
Journal of Clinical Pathways
News
Cost-Effectiveness of Nivolumab vs Pembrolizumab for Head and Neck Cancer
08/18/2021
Both the willingness-to-pay threshold and patient body weight need to be considered when deciding between nivolumab and pembrolizumab for treating platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma.
Both the willingness-to-pay threshold and patient body weight need to be considered when deciding between nivolumab and pembrolizumab for treating platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma.
Both the willingness-to-pay...
08/18/2021
Journal of Clinical Pathways
News
What Are the Costs Associated With Imaging Surveillance After Treatment for Head and Neck Cancer?
08/11/2021
Study findings suggest that many patients with head and neck cancers received imaging beyond what is recommended by the NCCN guidelines, and the cost burden of imaging asymptomatic patients needs to be considered.
Study findings suggest that many patients with head and neck cancers received imaging beyond what is recommended by the NCCN guidelines, and the cost burden of imaging asymptomatic patients needs to be considered.
Study findings suggest that many...
08/11/2021
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness of Temozolomide Use in Patients with Glioblastoma
06/02/2021
Study findings support post-radiation clinical trial enrollment instead of temozolomide for unmethylated patients with glioblastoma.
Study findings support post-radiation clinical trial enrollment instead of temozolomide for unmethylated patients with glioblastoma.
Study findings support...
06/02/2021
Journal of Clinical Pathways
NCCN Updates Clinical Practice Guideline for Central Nervous System Cancers
Guideline Updates
NCCN Updates Clinical Practice Guideline for Central Nervous System Cancers
03/24/2021

Janelle Bradley

Janelle Bradley
NCCN released an update to its clinical practice guideline for central nervous system cancers, adding lorlatinib as a category 2A recommendation for brain metastases from NSCLC.
NCCN released an update to its clinical practice guideline for central nervous system cancers, adding lorlatinib as a category 2A recommendation for brain metastases from NSCLC.
NCCN released an update to its...
03/24/2021
Journal of Clinical Pathways
NCCN Updates Clinical Practice Guideline for Esophageal Cancers
NCCN Updates Clinical Practice Guideline for Esophageal Cancers
03/10/2021

Janelle Bradley

Janelle Bradley
The National Comprehensive Cancer Network released an update to its clinical practice guideline for esophageal and esophageal junction cancers.
The National Comprehensive Cancer Network released an update to its clinical practice guideline for esophageal and esophageal junction cancers.
The National Comprehensive...
03/10/2021
Journal of Clinical Pathways
Quiz
Quiz: Cetuximab vs Cisplatin for Locoregional Control of HNSCC
02/01/2021
02/01/2021
Journal of Clinical Pathways

Newsfeed

News
Analyzing Billing Patterns and Medicare Reimbursement Among Otolaryngologists Performing In-Office Cerumen Removal
09/12/2022

Yvette C Terrie

Yvette C Terrie
General physicians and other providers are progressively referring patients requiring cerumen disimpaction to otolaryngologist physicians and permitting advanced practice providers to perform these procedures, suggesting a shift in landscape...
General physicians and other providers are progressively referring patients requiring cerumen disimpaction to otolaryngologist physicians and permitting advanced practice providers to perform these procedures, suggesting a shift in landscape...
General physicians and other...
09/12/2022
Journal of Clinical Pathways
News
Model Predicts Presence of Occult Nodal Metastasis Better Than Current Standard in Early-Stage Oral Cavity Squamous Cell Carcinoma
05/18/2022

Ellen Kurek

Ellen Kurek
Machine learning models that were developed from multi-institutional clinicopathologic data may reduce the number of pathologically node-negative neck dissections and accurately identify patients with early OCSCC who are at highest risk for...
Machine learning models that were developed from multi-institutional clinicopathologic data may reduce the number of pathologically node-negative neck dissections and accurately identify patients with early OCSCC who are at highest risk for...
Machine learning models that...
05/18/2022
Journal of Clinical Pathways
News
Decision Analytical Model Optimizes Posttreatment Surveillance Strategies Among Patients With Oropharyngeal Carcinoma
04/29/2022

Marta Rybczynski

Marta Rybczynski
When compared with common medical reimbursement guidelines, model-optimized strategies may be associated with lower detection latency without requiring any additional imaging studies among patients with oropharyngeal carcinoma.
When compared with common medical reimbursement guidelines, model-optimized strategies may be associated with lower detection latency without requiring any additional imaging studies among patients with oropharyngeal carcinoma.
When compared with common...
04/29/2022
Journal of Clinical Pathways
News
Medicare Reimbursement Decreased from 2000 to 2020 in Head and Neck Surgical Oncology
04/26/2022

Ellen Kurek

Ellen Kurek
Medicare reimbursement decreased from 2000 through 2020 for the 37 most common head and neck surgical oncologic procedure codes considered as a group, according to a recent analysis.
Medicare reimbursement decreased from 2000 through 2020 for the 37 most common head and neck surgical oncologic procedure codes considered as a group, according to a recent analysis.
Medicare reimbursement decreased...
04/26/2022
Journal of Clinical Pathways
News
Cost-Effectiveness of Nivolumab vs Pembrolizumab for Head and Neck Cancer
08/18/2021
Both the willingness-to-pay threshold and patient body weight need to be considered when deciding between nivolumab and pembrolizumab for treating platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma.
Both the willingness-to-pay threshold and patient body weight need to be considered when deciding between nivolumab and pembrolizumab for treating platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma.
Both the willingness-to-pay...
08/18/2021
Journal of Clinical Pathways
News
What Are the Costs Associated With Imaging Surveillance After Treatment for Head and Neck Cancer?
08/11/2021
Study findings suggest that many patients with head and neck cancers received imaging beyond what is recommended by the NCCN guidelines, and the cost burden of imaging asymptomatic patients needs to be considered.
Study findings suggest that many patients with head and neck cancers received imaging beyond what is recommended by the NCCN guidelines, and the cost burden of imaging asymptomatic patients needs to be considered.
Study findings suggest that many...
08/11/2021
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness of Temozolomide Use in Patients with Glioblastoma
06/02/2021
Study findings support post-radiation clinical trial enrollment instead of temozolomide for unmethylated patients with glioblastoma.
Study findings support post-radiation clinical trial enrollment instead of temozolomide for unmethylated patients with glioblastoma.
Study findings support...
06/02/2021
Journal of Clinical Pathways
News
Deep Learning Models for Image-Guided RT in Head and Neck and Prostate Cancers
12/10/2020
Machine learning models achieve clinically acceptable accuracy in image segmentation tasks in radiotherapy planning and reduce overall contouring time for head and neck and prostate cancers.
Machine learning models achieve clinically acceptable accuracy in image segmentation tasks in radiotherapy planning and reduce overall contouring time for head and neck and prostate cancers.
Machine learning models achieve...
12/10/2020
Journal of Clinical Pathways
News
FDA Approves Pralsetinib for Thyroid Cancers Harboring RET Alterations
12/01/2020
12/01/2020
Journal of Clinical Pathways
News
Cetuximab Inferior to Cisplatin for Locoregional Control of HNSCC
11/23/2020
11/23/2020
Journal of Clinical Pathways
News
Examining Treatment Delay Trends in Patients With Lung Cancer
07/24/2024
A study in Missouri uncovers a disturbing trend of increasing delays in lung cancer treatment initiation, surpassing national guidelines and prompting a call for further investigation into potential causes.
A study in Missouri uncovers a disturbing trend of increasing delays in lung cancer treatment initiation, surpassing national guidelines and prompting a call for further investigation into potential causes.
A study in Missouri uncovers a...
07/24/2024
Journal of Clinical Pathways
Laura Bray
Videos
Advocacy to Reduce the Impact of Drug Shortages on Cancer Care
07/23/2024
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her...
07/23/2024
Journal of Clinical Pathways
News
First-Line Amivantamab Plus Lazertinib Superior to Osimertinib Among Patients With Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
07/18/2024
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3...
07/18/2024
Oncology
Steve Kalloger, MSc
Videos
Trends in Therapeutic Utilization Among Patients With CLL: Results From the Lymphoma Coalition’s 2022 Global Patient Survey Presented at ASCO 2024
07/18/2024
Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).
Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).
Steve Kalloger, MSc, discusses...
07/18/2024
Journal of Clinical Pathways
News
Perioperative Nivolumab Prolonged Event-Free Survival Compared to Perioperative Chemotherapy Among Patients With Resectable Non-Small Cell Lung Cancer
07/15/2024
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3...
07/15/2024
Oncology
Stephen Colvill, MBA
Conference Coverage
How Collaboration Among Health Care Stakeholders Can Help Mitigate Drug Shortages
07/08/2024
Stephen Colvill, MBA, discusses how collaboration, proactive strategies, and technology can help prevent drug shortages.
Stephen Colvill, MBA, discusses how collaboration, proactive strategies, and technology can help prevent drug shortages.
Stephen Colvill, MBA, discusses...
07/08/2024
Journal of Clinical Pathways
News
Improving Care for Patients With Cancer Through Early Goal of Care Discussions
07/03/2024
Standardizing electronic documentation of physician-led goals of care discussions in patients with cancer can lead to improved care integration across health care settings, ensuring comprehensive and individualized quality care for patients...
Standardizing electronic documentation of physician-led goals of care discussions in patients with cancer can lead to improved care integration across health care settings, ensuring comprehensive and individualized quality care for patients...
Standardizing electronic...
07/03/2024
Journal of Clinical Pathways
Conference Coverage
The Association Between High Deductible Health Plans and Cancer Survival
07/02/2024
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented...
07/02/2024
Journal of Clinical Pathways
News
Impact of Care Delays on Health Care Resource Utilization in Patients With Early-Stage Lung Cancer
06/26/2024

Brandon Twyford

Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
06/26/2024
Journal of Clinical Pathways
Moritz Furstenau, MD
Conference Coverage
Efficacy and ctDNA Analysis of MRD-Guided Acalabrutinib, Venetoclax, and Obinutuzumab for Patients With R/R CLL
06/26/2024

Featuring Moritz Furstenau, MD

Featuring Moritz Furstenau, MD ...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting,...
06/26/2024
Oncology

Interactive Features

Quiz
Quiz: Imaging Use Among Patients With Head and Neck Cancer
01/28/2022
True or False: Many patients with head and neck cancers receive imaging beyond what is recommended by the NCCN guidelines.
True or False: Many patients with head and neck cancers receive imaging beyond what is recommended by the NCCN guidelines.
True or False: Many patients...
01/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cetuximab vs Cisplatin for Locoregional Control of HNSCC
02/01/2021
02/01/2021
Journal of Clinical Pathways
Quiz
Quiz: Cisplatin Vs Cetuximab For Oropharyngeal Carcinoma With Concurrent Radiation
09/28/2020
09/28/2020
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicare Reimbursement in Head and Neck Surgical Oncology
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Biosimilar vs Referent Trastuzumab for ERBB2–Positive Breast Cancer
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Recent Stories

News
Analyzing Billing Patterns and Medicare Reimbursement Among Otolaryngologists Performing In-Office Cerumen Removal
09/12/2022

Yvette C Terrie

Yvette C Terrie
General physicians and other providers are progressively referring patients requiring cerumen disimpaction to otolaryngologist physicians and permitting advanced practice providers to perform these procedures, suggesting a shift in landscape...
General physicians and other providers are progressively referring patients requiring cerumen disimpaction to otolaryngologist physicians and permitting advanced practice providers to perform these procedures, suggesting a shift in landscape...
General physicians and other...
09/12/2022
Journal of Clinical Pathways
News
Model Predicts Presence of Occult Nodal Metastasis Better Than Current Standard in Early-Stage Oral Cavity Squamous Cell Carcinoma
05/18/2022

Ellen Kurek

Ellen Kurek
Machine learning models that were developed from multi-institutional clinicopathologic data may reduce the number of pathologically node-negative neck dissections and accurately identify patients with early OCSCC who are at highest risk for...
Machine learning models that were developed from multi-institutional clinicopathologic data may reduce the number of pathologically node-negative neck dissections and accurately identify patients with early OCSCC who are at highest risk for...
Machine learning models that...
05/18/2022
Journal of Clinical Pathways
News
Decision Analytical Model Optimizes Posttreatment Surveillance Strategies Among Patients With Oropharyngeal Carcinoma
04/29/2022

Marta Rybczynski

Marta Rybczynski
When compared with common medical reimbursement guidelines, model-optimized strategies may be associated with lower detection latency without requiring any additional imaging studies among patients with oropharyngeal carcinoma.
When compared with common medical reimbursement guidelines, model-optimized strategies may be associated with lower detection latency without requiring any additional imaging studies among patients with oropharyngeal carcinoma.
When compared with common...
04/29/2022
Journal of Clinical Pathways
News
Medicare Reimbursement Decreased from 2000 to 2020 in Head and Neck Surgical Oncology
04/26/2022

Ellen Kurek

Ellen Kurek
Medicare reimbursement decreased from 2000 through 2020 for the 37 most common head and neck surgical oncologic procedure codes considered as a group, according to a recent analysis.
Medicare reimbursement decreased from 2000 through 2020 for the 37 most common head and neck surgical oncologic procedure codes considered as a group, according to a recent analysis.
Medicare reimbursement decreased...
04/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Imaging Use Among Patients With Head and Neck Cancer
01/28/2022
True or False: Many patients with head and neck cancers receive imaging beyond what is recommended by the NCCN guidelines.
True or False: Many patients with head and neck cancers receive imaging beyond what is recommended by the NCCN guidelines.
True or False: Many patients...
01/28/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement